Abstract:Backgrounds: Epidermal growth factor receptor (EGFR) mutation profiles play a vital role in treatment strategy decisions for non–small cell lung cancer (NSCLC). The purpose of this study was to evaluate the predictive efficacy of baseline 18 F-FDG PET/CT-based radiomics analysis for EGFR mutation status, mutation site, and the survival benefit of targeted therapy. Methods: A sum of 313 NSCLC patients with pre-treatment 18 F-FDG PET/CT scans and genetic mutations detection were retrospectively studied. Clinical and PET metabolic parameters were incorporated into independent predictors of determining mutation status and mutation site. The dataset was randomly allocated into the training and the validation sets in a 7:3 ratio. Three-dimensional (3D) radiomics features were extracted from each PET- and CT-volume of interests (VOI) singularly, and then a radiomics signature (RS) associated with EGFR mutation profiles is built by feature selection. Three different prediction models based on support vector machine (SVM), decision tree (DT), and random forest (RF) classifiers were established. Furthermore, nomograms for estimation of overall survival (OS) and progression-free survival (PFS) were established by integrating PET/CT radiomics score (Rad-score), metabolic parameters, and clinical factors. Predictive performance was assessed by the receiver operating characteristic (ROC) analysis and the calibration curve analysis. The decision curve analysis (DCA) was applied to estimate and compare the clinical usefulness of nomograms. Results: Three hundred thirteen NSCLC patients were classified into a training set (n=218) and a validation set (n=95). Multivariate analysis demonstrated that SUVmax and sex were independent indicators of EGFR mutation status and mutation site. Eight CT-derived RS, six PET-derived RS, and two clinical factors were retained to develop integrated models, which exhibited excellent ability to distinguish between EGFR wild type (EGFR-WT), EGFR 19 mutation type (EGFR-19-MT), and EGFR 21 mutation type (EGFR-21-MT). The SVM model outperformed the RF model and the DT model, yielding training area under the curves (AUC) of EGFR-WT, EGFR-19-WT, and EGFR-21-WT, with 0.881, 0.851, and 0.849, respectively, and validation AUCs of 0.926, 0.805 and 0.859, respectively. For prediction of OS, the integrated nomogram is superior to the clinical nomogram and the radiomics nomogram, with C-indexes of 0.80 in the training set and 0.83 in the validation set, respectively. Conclusions: The PET/CT-based radiomics analysis might provide a novel approach to predict EGFR mutation status and mutation site in NSCLC patients and could serve as useful predictors for the patients' survival outcome of targeted therapy in clinical practice.

The Use of Mutation-Specific Antibodies in Predicting the Effect of EGFR-TKIs in Patients with Non-Small-cell Lung Cancer

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Detection of EGFR gene mutations with mutation-speciifc immunohistochemistry in non-small cell lung cancer

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Predicting Significance of EGFR Mutation Existing in Tissues and Plasma Concuurrently or Alone to EGFR–tyrosine Kinase Inhibitors (Egfr-Tkis) for Advanced Non-Small Cell Lung Cancer.

The Predictive Values of Mutation Patterns, Concurrent Mutations and Efficacy of Different Generations of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Harboring Non-Resistant Uncommon EGFR Mutations.

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Analysis of Egfr Mutation Status in Tissue and Plasma for Predicting Response to Egfr-Tkis in Advanced Non-Small-Cell Lung Cancer

Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

Epidermal Growth Factor Receptor Mutations In Plasma Dna Samples Predict Tumor Response In Chinese Patients With Stages Iiib To Iv Non-Small-Cell Lung Cancer

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA

The Potential Of Radiomics Nomogram In Non-Invasively Prediction Of Epidermal Growth Factor Receptor Mutation Status And Subtypes In Lung Adenocarcinoma

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI

Predictive value of spectral computed tomography parameters for EGFR gene mutation in non-small-cell lung cancer

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

Prognostic and Predictive Value of Serum Carcinoembryonic Antigen Levels in Advanced Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Sensitive Mutations and Receiving Tyrosine Kinase Inhibitors.